Abstract submission guidelines

Abstract Submission Now Closed

Call for abstract submissions have now closed. The scientific committee is currently reviewing the abstracts. You will be notified of your outcome by the end of May.

All accepted abstract presenters will be provided with a registration code to access the early bird registration rate.

Call for abstracts open

Wednesday 15 December 2021

Call for abstracts close

Friday 6 May 2022

Applicants notification

May 2022

All abstract submissions must be received electronically through the online submission portal. Use the submit now button to start your submission!

ABSTRACT INFORMATION
  • Please note that all correspondence will be sent to the email address you provide when uploading your abstract
  • Applicants whose abstract is accepted must be a registered attendee.
  • A link will be sent to the main author to register. Any costs incurred remain at the responsibility of the presenting author.
ABSTRACT THEMES

We welcome delegates to submit their abstracts for the 2022 ASM under the following categories:

  • Neuro oncology
  • Solid tumours
  • Leukaemia/Lymphoma
  • Non malignant haematology
  • Transplant and cellular therapy
  • Patient experience
  • Other


We encourage you to submit abstracts from all disciplines and fields, including basic and translational science, clinical care, psychosocial impact and late effects.

We welcome submissions across all patient age groups, and encourage junior and senior investigators to submit their research.

ABSTRACT AWARDS

The top 3 abstracts submitted will be selected for presentation at a plenary session.

Prizes will also be awarded to the best abstracts in the following  categories:

  • Junior investigator – clinical         
  • Junior investigator – basic and translational science
  • Nursing
  • Allied health
ABSTRACT REVIEW
  • All abstracts will be reviewed by the abstract review committee to ensure the quality and compatibility with the conference.
  • Abstracts will be reviewed on a competitive basis and successful applicants will be notified accordingly.
  • The final decision on acceptances and on publication and presentation formats are at the discretion of the abstract review committee.
POSTERS
  • Successful applicants will be required to display the poster at the conference utilising the standarise poster template
  • They must be available to stand by their poster to discuss the poster findings as required during the meeting breaks
  • Posters can be printed on paper or fabric and/or laminated and we recommend using Velcro to mount material on the panel as poster boards will be Velcro compatible. by individual presenter.
  • Posters will be displayed on free-standing horizontal boards. Your poster space allocation is AO size, portrait (1189mm high x 841mm wide – maximum size).
  • Presenters are required to hang their posters prior to the Morning tea on Thursday 28 July 2022.
  • Posters will be available for the duration of the conference.

The printer we recommend is listed below;

IMPORTANT INFORMATION
  • All abstracts submitted must be original work and cannot be previously presented in any form, unless agreed in writing by the Local Organising Committee.
  • Abstracts must be submitted by the presenting author 
  • Successful abstracts will be published within the Local Organising Committee’s discretion.
  •  Should you prefer that your abstract NOT be published, please advise the conference secretariat.
  • All successful applicants are required to register for the conference and pay the registration fee.
  • All presenters are required to register within 2 weeks of receiving their notification
  • Any abstract that does not comply with these specifications may not be accepted for review.
FURTHER QUESTIONS

For any enquiries regarding abstracts or the abstract’s submission process, please do not hesitate to contact our conference secretariat on:
Email: info@anzchog2022.com
Phone: +61 7 3858 5400

Echo Therapeutics is an Australian Pharmaceutical and Medical Technology Company, specialising in products and services for the Hospital sector in Australia and New Zealand. Our aim is to gain deep customer insights to resolve unmet needs.

Partnering with global and local groups, we will build complementary suites of products and services for the ANZ markets that will have a meaningful impact on our customers and patients lives.

Our goal is to work with ANZCHOG to improve access to medicines in paediatric oncology.

Vencare Medical

ECP made EASY! Flexible two-step ECP that works for you! info@vencaremedical.com.au

Leukaemia & Blood Cancer New Zealand (LBC) is New Zealand’s national charity dedicated to supporting patients, and their families/whānau, living with a blood cancer or a serious blood condition.

At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases.

Through bold and transformative science, we’re driving innovation that has the potential to become the next generation of life-changing medicines. Our ambition is evident in our mission. Because the impossible is not impossible. It’s what’s next.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Novartis has more than 60 years’ history in Australia and employ around 600 associates across its two divisions.

A/Prof Jordan Hansford

Women’s and Children’s Hospital Adelaide

Jordan is a mid-career clinician specializing in the treatment of paediatric brain tumours. He has a long-standing interest in cancer genetics post the completion of his Master’s of Science in Cancer Genetics at Queen’s University, Canada. Upon the completion of his clinical training and admission to fellowship, he relocated to Melbourne where he led the team’s neuro-oncology and clinical research teams. Most recently he has relocated to Adelaide where he is developing a Neuro-Oncology research program at SAHMRI/SAiGENCI and the new Bragg Proton Radiotherapy Centre. He is currently the chair of the ANZCHOG brain group.

Proudly supported by

Jazz Pharmaceuticals is a global Biopharmaceutical Company whose purpose is to transform the lives of patients and their families through innovation. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options so they can live their lives more fully.

We have a diverse portfolio of marketed medicines and novel product candidates, from early- to latestage development, in Neuroscience and Haematology/Oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science.

Jazz Pharmaceuticals has employees around the globe including Australia and New Zealand, serving patients in nearly 75 countries

Medical Information
Phone: 1800577422
Email: medinfo-apac@jazzpharma.com

Adverse event
Phone: 1800577422
Email: AEReporting@jazzpharma.com


To report a Product Complaint, please email:
productcomplaints@jazzpharma.com

For more than 20 years, Illumina has aspired to improve human health by unlocking the power of the genome. As we move towards precision medicinein pediatric cancer, we have only just begun to discover the true impact of genomics. Learn how Illumina technologies is enabling novel insights into childhood cancer risk and treatment. Visit: https://sapac.illumina.com/destination/Precision-Medicine-in-Pediatric-Cancers.html

eviQ and eviQ Education are programs of the Cancer Institute NSW, a state government cancer control agency. Both programs have a national target audience and an international reach.

eviQ provides free online evidence-based, consensus driven cancer treatment protocols and information for use at the point of care. eviQ is developed for the Australian context and supports health professionals in the delivery of cancer treatments.

eviQ Education provides free, evidence-based cancer eLearning resources for health professionals.

BD is one of the largest global medical technology companies in the world and is advancing the world of healthTM by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.

Our history
The Kids’ Cancer Project is an independent national charity supporting childhood cancer research. Since 1993, the charity has contributed more than $50 million dollars to scientific research projects to help children with many different types of cancer.

Our Goal
Mission: To support bold scientific research that has the greatest chance of clinical success in the improvement of treatments of childhood cancers.

Vision: One hundred per cent survival for children with cancer while eradicating the harmful impacts treatment can bring.

What we stand for
Science: We believe the only way to improve outcomes for kids with cancer is through advances in medical research.

Solutions: Our research priorities reflect our focus on finding better treatments, building research capabilities and supporting survivorship programs.

Survival: Our founder, Col Reynolds OAM, made a promise
to never give up until a cure is found.

The Robert Connor Dawes (RCD) Foundation was created in June 2013 in the memory of Robert ‘Connor Dawes’ who lost his 16-month battle with an ependymoma brain tumour at just 18 years of age. The RCD Foundation works to support brain matters projects in the areas of research, care and development – to fund the science to fight paediatric brain cancer and support patients in the meantime.

The Foundation operates in Australia and the US, and to date has invested $3.45M into paediatric brain cancer research, funding basic science and translational projects, as well as capacity building grants through fellowships, scholarships and travel grants. It has also leveraged another $10M, leading collaborative research initiatives. In addition to funding and partnering with Australian research institutes and Foundations, RCD is also active member of the Child’s Brain Tumour Network (CBTN), Paediatric Neuro-Oncology Consortium (PNOC) and the Collaborative Ependymoma Research Network (CERN). We leverage our research investments through partnering with like-minded and passionate organisations to continue to battle paediatric brain cancer.

Breakthroughs That Change Patients’ Lives: Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and significantly improve lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Servier is a privately owned pharmaceutical company, governed by a non-profit foundation that is committed to therapeutic progress to serve patient needs. Servier has a long-standing commitment to research and development.

Worldwide approximately 25% of branded product turnover is reinvested into research and development through the Servier Foundation, with half of that investment dedicated to research to help fight cancer.
Servier has significant investment in new products in early development in the areas of Oncology and Haematology with broad research and development platforms in cancer cell apoptosis and immuno-oncology. Servier Australia is also home to the Asia-Pacific clinical trial hub.
Servier is proud to support innovative partnering programs with world class institutions including WEHI in Australia to further advance scientific understanding in the area of oncology. For further information see the website www.servier.com.au

Servier Australia’s oncology products include Oncaspar (pegaspargase), Lonsurf® (trifluridine/tipiracil) and Onivyde® (nanoliposomal irinotecan as sucrosofate).

MISSION: WE CHANGE LIVES, PATIENT BY PATIENT

At EUSA we are committed to transforming the lives of people affected by cancer or rare disease, globally.

We continuously strive to uncover opportunities which address gaps across adult and paediatric care – through development opportunities, acquiring, and in-licensing therapies.

Helping the people with few or no options available is at the heart of everything we do at EUSA. Every day, we are proud to make a difference – building a company around our people, our values, and our mission.

We see a need. We work together. We don’t give up.

Bayer is a global life science company with expertise in healthcare and agriculture. The company has had a presence in Australia since 1925 and has a long-term commitment to the health and nutrition of all Australians and New Zealanders. As people live longer and the population continues to grow both locally and beyond, Bayer is one of the few companies that takes a comprehensive view of these issues. Guided by our purpose – Science for a better life – we apply our global scientific expertise in healthcare and agriculture to deliver innovations locally to help people and the planet thrive.

Bayer employs almost 900 people across Australia and New Zealand and is dedicated to servicing the needs of rural and remote communities. Bayer embraces and encourages its employees’ unique identities and advances a culture of inclusion and diversity across gender, LGBTQIA+, generations, disability and race.

For further information visit www.bayer.com.au

Dr Robert Battisti

Children’s Hospital Westmead

Dr Battisti is a Clinical Psychologist and Researcher at the Cancer Centre for Children at the Children’s Hospital at Westmead, and an Honorary Research Associate at the University of Sydney. Dr Battisti completed his PhD at the University of Wollongong and a postdoctoral position with the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales in partnership with the Brain and Mind Centre at the University of Sydney. Dr Battisti is also on the Board of Directors for the Australian Clinical Psychology Association (ACPA). His clinical background is in child, adolescent and young adult (AYA) psychology as well as parenting psychology, with expertise in paediatric cancer including childhood cancer survivorship.

Annabel Crabb

ABC Journalist

Annabel Crabb is one of Australia’s most beloved journalists. She is an ABC writer and presenter who has covered Australian politics for 20 years but also is nationally well-known for her insightful and humorous analysis on gender and current affairs. 

Annabel recently created and presented the ground breaking Ms Represented, unearthing stories from the 100 years of women in Australian parliaments. For the ABC, she has also devised and presented six seasons of the enormously popular Kitchen Cabinet, and “The House with Annabel Crabb – the fly-on-the-wall documentary on Australian Parliament.” She also presents the ABC’s hit culinary history series Back In Time For Dinner, and co-stars in Tomorrow Tonight with Charlie Pickering.

With friend and ABC colleague Leigh Sales, Australia’s pre-eminent current affairs journalist, Annabel hosts the top-rating podcast Chat 10 Looks 3. Their first book together, Well Hello, was published in September 2021.

Annabel is an avid baker and proud mother of three.

Prof Marcus Vowels

Professor Vowels is a renowned early leader of the paediatric oncology and haematology disciplines in Australia. Professor Vowels established the first bone marrow transplant program in Australia at the then Prince of Wales Children’s Hospital, now Sydney Children’s Hospital in Randwick, NSW. Professor Vowels established the Australian Cord Blood Bank and was a founding trustee of the Australian Cord Blood Foundation. Professor Vowels has over 100 peer reviewed publications, he was the founding member of a number of editorial boards of discipline specific journals and is the author of multiple book chapters. Professor Vowels was the President of the Australian and New Zealand Children’s Cancer Study Group from 1990 to 1994, and was awarded a Member of the Order of Australia (AM) for his service to medicine, particularly in the fields of childhood leukaemia and cancer.

Prof Paul Monagle

University of Melbourne

Professor Monagle is an internationally renowned paediatric haematologist and haemato-pathologist. He is a Professor of Paediatrics at the University of Melbourne, a clinical Haematologist at the Kids Cancer Centre, Sydney Children’s Hospital, and an Honorary Fellow and Group Leader in Haematology Research at the Murdoch Children’s Research Institute. Professor Monagle is a world expert on thrombosis and coagulation, with over 300 publications in the field of paediatric haematology. His research group holds multiple NHMRC grants and is currently leading work into COVID-19 associated thrombosis. Professor Monagle was awarded the Outstanding Research Award in Paediatric Cardiology by the American Heart Association in 2008, and delivered the Barry Firkin Oration for the Thrombosis & Haemostasis Society of Australia and New Zealand in 2018. He has played a key role in designing multiple international multi-centre trials, and been an invited speaker at haematology conferences across the globe.

Dr Robert Battisti

Children’s Hospital Westmead

DR ROB BATTISTI | CLINICAL PSYCHOLOGIST | BPSYCH (HONS), PhD (CLINICAL PSYCHOLOGY) | FACPA | LEUT RAN

Rob Battisti is a Senior Clinical Psychologist and head of Psycho-oncology at the Cancer Centre for Children at the Children’s Hospital at Westmead and a Clinical Director at Mind Plasticity, a large multi-disciplinary mental health practice in Sydney. He is passionate about delivering evidence-based therapies and overcoming some of the traditional barriers that restrict people from accessing top quality care via team care arrangements. A key focus of his work is mental health service development, including policy, governance and clinical training. His goal in children’s cancer services is to ensure that mental wellness, education and future quality of life are placed firmly in the treatment mix.

Rob completed his PhD at the University of Wollongong and a postdoctoral position with the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales in partnership with the Brain and Mind Centre (BMC) at the University of Sydney. He has worked in and around Sydney for many years and has professional affiliations with organisations such as the BMC, headspace and St Vincent’s Private Hospital. He has additionally served on the Board of Directors for the Australian Clinical Psychology Association (ACPA) of which he is a Fellow member.

Rob has expertise in working with individuals and families with more complex needs and in multi-disciplinary care arrangements. His clinical background is in child, adolescent and young adult (AYA) psychology as well as parenting psychology, with expertise in cancer and other areas of health psychology, addiction, and psychiatric comorbidity (i.e. multiple diagnoses).

Rob also consults to organisations on preventative mental health and is a Lieutenant Psychologist with the Royal Australian Navy.

Dr Justin Baker

St Jude Children’s Research Hospital

Dr Baker is the Division Chief of Quality of Life and Palliative Care at St. Jude Children’s Research Hospital, Memphis, TN, USA. He is trained in paediatric haematology/oncology, as well as Hospice and Palliative Medicine. Dr Baker is a world leader in paediatric palliative care and quality of life, with over 100 publications in the field. His research focuses on integrating palliative care into the ongoing care of children with cancer, the ethical consideration of early phase trials, and paediatric palliative care in developing countries. He was awarded the AAHPM Inspirational Leader in Hospice and Palliative Medicine in 2014, and the St. Jude Communicator of the Year in 2017. Dr Baker has led the development of guidelines in paediatric palliative care and quality of life that have been implemented in centres throughout the world, and has been an invited speaker at paediatric oncology and palliative care conferences across the globe.

Proudly supported by

A/Prof Yasmin Jayasinghe

The Royal Children’s Hospital Melbourne

AProf Yasmin Jayasinghe (FRANZCOG, PhD) is a paediatric gynaecologist , Director of the Oncofertility Program at The Royal Children’s Hospital Melbourne and the Australian representative on the Practice Committee of the global Oncofertility Consortium.  She is founding Chair of the Australian New Zealand Consortium in Paediatric Oncofertility (ANZCO), and is Principal Investigator of the binational ANZCO clinical trials network driven by ANZCHOG champions, who were recently awarded  a $3million MRFF for ‘Life Saving and Job Creating Medical Research’. She was founding chair of the Fertility Preservation Taskforce in Victoria in 2012, who in partnership with consumers pioneered Australia’s first ethically governed paediatric oncofertility program, oncofertility registry (scaled up to the Future Fertility Registry by A Anazodo), and oncofertility nurse navigators. The taskforce have been recognized as finalists in: the Vic Health Awards for facilitating equitable access to oncofertility care; the Australian Nurse of the Year awards for nurse navigation; and three statewide Young Achiever Awards for oncofertility innovation. AProf Jayasinghe has received many honours and in 2021 was a national finalist for the Australian Human Rights Medal for pioneering the protection of the reproductive rights of children.

Join the ANZCHOG ASM mailing list

Stay informed with the latest updates
* indicates required